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ABSTRACT
Objective: To evaluate the efficacy, safety and tolerability of sildenafil among Brazilian
patients with hypertension treated with combinations of anti-hypertensive drugs.
Materials and Methods: One hundred twenty hypertensive men aged 30 to 81 years old
under treatment with 2 or more anti-hypertensive drugs and with erectile dysfunction (ED) lasting for
at least 6 months were enrolled at 7 research centers in Brazil. Patients were randomized to receive
treatment with either sildenafil or placebo taken 1 hour before sexual intercourse (initial dose of 50
mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity). During the following 8 weeks,
patients were evaluated regarding vital signs, adverse events, therapeutic efficacy, satisfaction with
treatment and use of concurrent medications.
Results: The primary evaluation of efficacy, which was based on responses to questions 3
and 4 of the International Index of Erectile Function, showed significant differences regarding treat-
ment with sildenafil (p = 0.0002 and p < 0.0001, respectively). In the assessment of global efficacy,
87% of the patients treated with sildenafil reported improved erections, as compared with 37% of
patients given placebos (p < 0.0001). The other secondary evaluations supported the results favoring
sildenafil. The most frequent adverse events among patients treated with sildenafil were headaches
(11.4%), vasodilation (11.4%) and dyspepsia (6.5%). There were no significant changes in blood
pressure measurements in both groups.
Conclusion: Sildenafil is efficacious and safe for the treatment of hypertensive patients with
ED who receive concurrent combinations of anti-hypertensive drugs.
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INTRODUCTION
Erectile dysfunction (ED) is defined as the
persistent inability to achieve and/or maintain an erec-
tion sufficient for sexual intercourse (1). ED is multi-
factorial and associated with several risk factors, such
as hypertension, diabetes mellitus, peripheral vascu-
lar and coronary artery disease, neurological diseases,
alcohol abuse, smoking, depression and others. The
prevalence of ED varies according to age and the pres-
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ence of co-morbidities. In addition, the proportion of
men that report ED varies from country to country
(2). According to a recent survey, approximately 46%
of Brazilian men report some degree of ED, which
may lead to an impaired quality of life in many cases
(3).
Hypertension is a public health problem of
global proportions. Although national estimates are
scarce and may not represent the overall population,
regional surveys have shown that the prevalence of
hypertension in Brazil varies from 22% to 44% (4).
Hypertension is frequently accompanied by other
medical problems, including dyslipidemias, diabetes
mellitus, heart disease and smoking, which may also
cause or aggravate ED. It has recently been estimated
that 42% of American men with ED are also hyper-
tensive (5). Men with hypertension have an up to four-
fold increase in the risk of developing ED, especially
with the use of drugs such as beta-blockers and
thiazides, which may have ED as side effects (6,7).
Among patients with hypertension, ED may decrease
the quality of life, self-esteem and the relationship
with a partner. Although the exact pathogenesis of
ED in men with hypertension has not been fully elu-
cidated, in many cases psychogenic factors accom-
pany the organic abnormalities that are secondary to
hypertension, thus contributing to the aggravation of
ED.
Several clinical trials have demonstrated the
efficacy of sildenafil in the treatment of ED with
various causes (8-10). Most adverse events reported
in the clinical studies of sildenafil, including head-
aches, flushing and nasal congestion are thought to
be related to the vasodilating properties of the drug.
The incidence of these adverse events increases with
higher doses of sildenafil. The possibility of poten-
tiating the effect of anti-hypertensive medications
has been a major concern regarding the use of
sildenafil for the treatment of hypertensive men with
ED. Preliminary clinical trials have not shown clini-
cally significant changes in blood pressure levels
among patients who were treated with sildenafil and
concurrent anti-hypertensive medications. There is,
however, little information in the literature regard-
ing the use of regimens of multiple anti-hyperten-
sive drugs (11).
The objective of the present study is to in-
vestigate the efficacy, safety and tolerability of
sildenafil in outpatients with hypertension and who
were on treatment with combinations of anti-hyper-
tensive drugs.
MATERIALS AND METHODS
Inclusion and Exclusion Criteria
Eligible patients were men aged 18 years or
older who had had a stable sexual relationship for the
previous 6 months, with a clinical diagnosis of ED of
at least 6 months’ duration, and with hypertension
that was being treated with at least 2 drugs from any
of the following classes: diuretics, alpha-blockers,
beta-blockers, angiotensin converting enzyme (ACE)
inhibitors, or calcium-channel blockers. To be eligible
for the study, patients also had to have a score ≤ 25 in
the erectile function domain of the International In-
dex of Erectile Function (IIEF) (12). Exclusion crite-
ria were any of the following: concurrent treatment
with nitrates, the presence of any genital deformity
or sexual disturbance that precluded sexual inter-
course, the use of any form of treatment for ED within
the 4 weeks preceding enrollment, alcohol or drug
abuse, the presence of retinitis pigmentosa, degen-
erative retinopathy or any major medical condition,
and the inability to fill in the event log or comply
with the study. The protocol was reviewed and ap-
proved by the Institutional Review Boards of all par-
ticipating centers, and all patients enrolled in the study
provided written informed consent.
Study Design
Candidate patients were initially evaluated
through a complete history, including sexual func-
tion, and a complete physical examination, including
the determination of blood pressure (BP) and heart
rate in sitting and in supine position. On the initial
visit, patients also underwent laboratory exams (com-
plete blood count, sodium, potassium, creatinine, glu-
cose, transaminases, cholesterol, triglycerides, pro-
lactin, testosterone and urinalysis) and electrocardio-
gram. Four weeks later, eligible patients were ran-
domized to receive treatment with sildenafil or pla-
cebo. Randomization was achieved through computer-
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generated blocks of random numbers. Sildenafil and
placebo tablets had the same appearance and were
dispensed in identical containers. Patients were in-
structed to take the study drug 1 hour before intended
sexual intercourse and not more than once daily. Based
on previous studies, the initial dose of sildenafil was
50 mg. In subsequent visits, this dose could be in-
creased to 100 mg or decreased to 25 mg depending
on efficacy and tolerability. Patients were evaluated
2, 4 and 8 weeks after randomization. Vital signs, the
use of concurrent medications, compliance and the
results obtained with the study treatment were as-
sessed at each visit. Treatment could last for a maxi-
mum of 8 weeks.
Assessment of Efficacy, Safety and Tolerability
Patients were instructed to record in the event
log the amount of medication taken and the results
achieved with treatment. The intent-to-treat (ITT)
population was defined as those patients who took at
least one dose of a study drug and recorded at least
one efficacy measurement during treatment. In addi-
tion, the sample of patients who could be evaluated
was comprised of those with complete follow up and
responses to the IIEF questions during the study. The
assessment of efficacy was done in these patients. The
primary efficacy parameter was the difference in pre-
treatment and post-treatment scores for questions 3
and 4 of the IIEF. Secondary measures of treatment
efficacy were the difference in pre-treatment and post-
treatment scores for other questions and for the do-
mains of the IIEF, patients’ responses to the Erectile
Dysfunction Inventory of Treatment Satisfaction
questionnaire (EDITS) (13) and the assessment of
global efficacy, and the proportion of successful at-
tempts at sexual intercourse. Patients were instructed
to register all symptoms experienced during the study,
and also to report promptly in the event of a serious
adverse effect. All cases of treatment interruption were
recorded, regardless of the cause leading to discon-
tinuation.
Statistical Analysis
Based on the assumption that the minimum
clinically relevant treatment difference between
sildenafil (combined dose groups) and placebo with
regards to IIEF scores (questions 3 and 4) is 0.75 and
that the common variance is 2.3, sample sizes of at
least 65 subjects per treatment group (sildenafil and
placebo) were required to detect the specified differ-
ence between the two treatment groups, with a power
of 80% and a type I error rate of 5%. The compari-
sons between groups regarding the change from
baseline in IIEF questions were assessed with un-
paired Student’s t test. Mann-Whitney tests were ap-
plied to compare the two groups regarding each ques-
tion of the EDITS questionnaire. Comparisons be-
tween sildenafil and placebo groups regarding the
behavior of BP during the study, were done using
analysis of variance for repeated measurements.
Multiple comparisons were based on Wald’s statis-
tics. The differences between proportions of satisfac-
tory responses in the assessment of global efficacy
were compared using the Pearson’s Chi-square test.
The proportion of successful attempts at intercourse
was compared between the two groups using a gen-
eralized estimation equation model assuming a uni-
form structure for the correlation. All hypothesis test-
ing considered a p value ≤ 0.05 as statistically sig-
nificant.
RESULTS
Patient Characteristics
One hundred and fifty-three patients were
recruited from seven research centers in Brazil. One
hundred and twenty patients took at least on dose of
the study drug; 87 of them completed the 8 weeks of
treatment and could be evaluated. Table-1 shows the
main demographic and clinical characteristics of the
ITT sample at baseline. There were no statistically
significant differences in any of these characteristics
between groups. The age of the patients varied be-
tween 30 and 81 years, the time since the start of ED
varied from 0.6 and 30 years, and the time since hy-
pertension was diagnosed varied from 2 to 52 months.
The etiology of erectile dysfunction, which was de-
termined on clinical grounds, was similar between
both groups, and approximately two-thirds of patients
had ED of mixed etiology.
The anti-hypertensive medication most fre-
quently utilized by the patients in both groups was a
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diuretic, followed by ACE inhibitors, calcium-chan-
nel blockers, beta-blockers and alpha-blockers (Fig-
ure-1). Patients remained on the same anti-hyperten-
sive regimen for the whole study period. Eighty-seven
Table 1 –  Patient characteristics at baseline (intent-to-treat sample, N  = 120)
Variable                                                              Sildenafil, N = 61 (%)              Placebo, N = 59 (%)
Age, years
Mean 59.4 60.6
Range 35 to 79 30 to 81
Smoking 13 (21.3) 15 (25.4)
Alcohol use 30 (49.2) 30 (50.2)
Duration of erectile dysfunction, years
Median 2.0 2.3
Range 0.6 to 24 0.6 to 30
Etiology of erectile dysfunction
Organic 11 (18) 11 (18.6)
Psychogenic 9 (14.8) 7 (11.9)
Mixed 41 (67.2) 41 (69.5)
Duration of hypertension, months
            Mean ± standard deviation 11.7 ± 9.0 11.2 ± 9.6
            Range 2 to 43 2 to 52
patients (44 in the sildenafil group and 43 in the pla-
cebo group) took 2 anti-hypertensive drugs, 27 pa-
tients (15 in the sildenafil group and 12 in the pla-
cebo group) took 3 anti-hypertensive drugs, and 6 (2
Figure 1 –  Anti-hypertensive drugs in both groups.
346
USE OF SILDENAFIL IN HYPERTENSIVE PATIENTS
in the sildenafil group and 4 in the placebo group)
took 4 or more anti-hypertensive drugs. The most fre-
quent co-morbidities were dyslipidemias, diabetes
mellitus and ischemic heart disease. The baseline elec-
trocardiogram was considered normal in 43% of the
patients; the most frequent abnormalities in the re-
maining cases were arrhythmias, aberrant electric
conduction and ventricular hypertrophy. There were
no significant changes in the electrocardiograph read-
ings between both groups.
Therapeutic Efficacy
At the conclusion of the study, 33 patients
(54.1%) were taking 50 mg of sildenafil, 24 (39.3%)
were taking 100 mg, and 4 patients (6.6%) were tak-
ing 25 mg. For patients taking the placebo, the pro-
portions were 20.3%, 74.6% and 5.1% respectively.
Compared with patients that took the placebo, patients
treated with sildenafil had more ability to achieve an
erection sufficient for sexual intercourse (p = 0.0002),
and also to maintain erections during the sexual in-
tercourse period (p < 0.0001) (Table-2). Similarly,
the differences between the scores for other IIEF ques-
tions before and after treatment, favored the group
treated with sildenafil. As shown in Table-3, with the
exception of questions 6, 9 and 11 of the IIEF (fre-
quency of intercourse, ejaculation and desire), all
other differences achieved statistical significance.
When the questions were grouped and the differences
were analyzed according to the IIEF domain, there
was a significant difference favoring sildenafil in four
of the five IIEF domains; the only domain for which
no such difference was evident was the sexual desire
domain (Figure-2).
The secondary efficacy analyses confirmed
the superiority of sildenafil over placebo for the treat-
ment of ED in patients who are on multiple anti-hy-
pertensive drugs. There were significant differences
favoring sildenafil in all 11 questions of the EDITS
questionnaire, and all statistical comparisons between
the two groups yielded p values of < 0.007. The as-
sessment of global efficacy showed that 87% of the
patients treated with sildenafil reported improvement
in their erections; this same proportion was 37%
among patients that took the placebo (p < 0.0001).
The analysis of event logs demonstrated statistically
significant differences between the two groups in the
proportions of successful attempts at sexual inter-
course. Among patients treated with sildenafil, suc-
cessful attempts were reported in 54%, 61% and 73%
of the times after 2, 4 and 8 weeks of treatment.
Among patients that took the placebo, these same
proportions were 13%, 20% and 29% (p < 0.0001 for
the comparison between groups at each time point).
Safety and Tolerability
Adverse Events
The analysis of safety and tolerability was
based on the ITT sample of 120 patients. Twenty-
Table 2 – Mean ± standard deviation scores on questions 3 and 4 of International Index of Erectile Function (IIFE).
Evaluable sample, N = 87.
IIFE
Questions
3) Penetration
     Ability
4) Maintenance
    Frequency
    Pre-
treatment
2.15 ± 1.37
2.04 ± 1.41
   Post-
treatment
4.04 ± 1.33
3.96 ± 1.40
Difference
1.89 ± 1.49
1.91 ± 1.71
    Pre-
treatment
2.05 ± 1.60
1.95 ± 1.56
   Post-
treatment
2.61 ± 1.63
2.24 ± 1.59
Difference
0.56 ± 1.75
0.29 ± 1.90
    P
0.0002
< 0.0001
P values refer to comparisons between differences. IIFE, International Index of Erectile Function.
Sildenafil (N = 46) Placebo (N = 41)
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IIFE
Questions
1) Erection
    Frequency
2) Erection
     Firmness
5) Maintenance
    Ability
6) Intercourse
    Frequency
7) Intercourse
    Satisfaction
8) Intercourse
    Enjoyment
9) Ejaculation
     Frequency
10) Orgasm
       Frequency
11) Desire
      Frequency
12) Desire
      Level
13) Overall
       Satisfaction
14) Relationship
       Satisfaction
15) Erection
      Confidence
    Pre-
treatment
2.26 ± 1.44
1.98 ± 1.34
2.09 ± 1.26
2.35 ± 1.39
2.09 ± 1.36
2.04 ± 1.09
3.20 ± 1.85
2.89 ± 1.66
3.41 ± 1.13
2.98 ± 0.72
2.11 ± 1.18
2.52 ± 1.26
2.41 ± 0.91
   Post-
treatment
4.22 ± 1.25
4.09 ± 1.26
4.20 ± 1.19
4.15 ± 1.28
4.15 ± 1.23
3.80 ± 1.00
4.24 ± 1.21
4.28 ± 1.17
4.04 ± 0.97
3.52 ± 0.91
4.15 ± 1.23
4.09 ± 1.09
3.63 ± 1.04
Difference
1.96 ± 1.33
2.11 ± 1.39
2.11 ± 1.37
1.80 ± 1.51
2.07 ± 1.50
1.76 ± 1.21
1.04 ± 1.76
1.39 ± 1.74
0.63 ± 1.39
0.51 ± 0.92
2.04 ± 1.50
1.57 ± 1.44
1.22 ± 0.99
    Pre-
treatment
2.00 ± 1.58
1.80 ± 1.36
2.22 ± 1.26
2.05 ± 1.38
1.76 ± 1.30
1.78 ± 1.27
2.39 ± 1.84
2.51 ± 1.78
3.39 ± 1.45
3.07 ± 1.03
2.15 ± 1.06
2.22 ± 1.11
2.24 ± 1.02
   Post-
treatment
2.59 ± 1.50
2.27 ± 1.50
2.63 ± 1.51
3.44 ± 1.38
2.34 ± 1.42
2.37 ± 1.26
2.93 ± 1.60
2.95 ± 1.63
3.83 ± 1.14
3.17 ± 0.83
2.32 ± 1.31
2.71 ± 1.44
2.41 ± 1.09
Difference
0.59 ± 1.28
0.46 ± 1.43
0.41 ± 1.86
1.39 ± 2.10
0.59 ± 1.84
0.59 ± 1.60
0.54 ± 1.89
0.44 ± 2.03
0.44 ± 1.34
0.10 ± 1.09
0.17 ± 1.26
0.49 ± 1.36
0.17 ± 1.20
      P
< 0.0001
< 0.0001
< 0.0001
= 0.2902
< 0.0001
< 0.0001
= 0.3206
= 0.0129
= 0.2966
= 0.0085
< 0.0001
= 0.0006
< 0.0001
Sildenafil (N = 46) Placebo (N = 41)
P values refer to comparisons between differences.
Table 3 – Mean ± standard deviation scores on questions 1, 2 and 5 to 15 of International Index of Erectile Function
(IIFE). Evaluable sample, N = 87.
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Figure 2  – Comparison between the efficacy of sildenafil and placebo, assessed by domains of the International Index of Erectile
Function (evaluable sample, N=87). P values refer to the difference between sildenafil and placebo in pretreatment and post-treatment
scores for each domain.
two patients had their treatment with the study drug
discontinued. Only 3 patients (1 treated with sildenafil
and 2 with placebo) had their treatments interrupted
due to adverse events. In all other cases, discontinua-
tion of treatment was due to insufficient clinical re-
sponse (1 case in the sildenafil group and 7 in the
placebo group) or other reasons (7 cases in the
sildenafil group and 4 in the placebo group). Adverse
events were registered in 82% of the patients treated
with sildenafil and in 40% of the patients that took
placebo. Of all these events, only 4 in each group
were graded as severe. Table-4 shows the most fre-
quent adverse events that were considered related to
study drugs. Among patients treated with sildenafil,
the most common adverse events were headache
(11.4% of the patients), vasodilation (11.4%) and
dyspepsia (6.5%). Four patients had serious adverse
events according to protocol definitions (cerebrovas-
cular accident, pulmonary edema/heart failure, atrial
fibrillation/arrhythmia and polytrauma); the former
3 events occurred in patients treated with sildenafil,
and the latter occurred in a patient that was taking
placebo. None of these events were deemed to be re-
Adverse Event
Vasodilation or
        facial flushing
Headache
Rhinitis
Dyspepsia
Dizziness
Abdominal pain
Paresthesia
Hypertension
Chest pain
Flu-like syndrome
Diarrhea
Total
     Sildenafil
         (N = 61)
8 (13.1%)
7 (11.4%)
6   (9.8%)
4   (6.5%)
2   (3.2%)
2   (3.2%)
2   (3.2%)
1   (1.6%)
1   (1.6%)
1   (1.6%)
1   (1.6%)
35 (57.3%)
Placebo
         (N = 59)
2   (3.4%)
2   (3.4%)
1   (1.7%)
0      (0%)
1   (1.7%)
1   (1.7%)
0      (0%)
3   (5.1%)
2   (3.4%)
2   (3.4%)
2   (3.4%)
16 (27.1%)
N Patients  (%)
Table 4 –  Adverse events occurring in 2% or more of patients
(intent-to-treat sample, N = 120).
lated to the study drugs. The case of poly-trauma was
secondary to a car accident, and this patient died dur-
ing the study.
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Behavior of the Blood Pressure (BP)
Figures-3 to 6 show patients’ BP behavior
during the 4 weeks of eligibility assessment and the 8
weeks of treatment, both in the supine (Figures-3 and
4) and seating (Figures-5 and 6) positions. There were
no significant changes between the BP measurements
when patients treated with sildenafil or placebo were
compared. In both groups, there were progressive
decreases in both systolic and diastolic BP readings
during the study.
COMMENTS
Several organic and psychological factors
interact to maintain a normal erectile function (1,14).
Penile erection is a hemodynamic event that depends
on the relaxation of the smooth muscle cells of the
trabeculae and arterioles of the corpora cavernosa. In
response to sexual stimulation, non-adrenergic non-
cholinergic nerve fibers and arteriolar endothelial cells
of the penis release nitric oxide (NO), a potent va-
sodilator that stimulates the activity of guanylate cy-
clase and leads to an increase in cyclic guanosine-
3',5'-monophosphate (cGMP). The ultimate effect is
calcium depletion from the cytosolic space and cav-
ernous smooth muscle relaxation. Phosphodiesterase
5 (PDE5), an enzyme that is present in the corpora
cavernosa, inactivates cGMP, thus terminating NO-
cGMP-mediated smooth muscle relaxation. Inhibition
of PDE5 enhances penile erection by preventing
cGMP degradation (15). Sildenafil is a potent and
selective inhibitor of PDE5 (16).
Figure 3 – Blood pressure (BP) behavior during the study. Systolic BP in the supine position. P values refer to the comparisons
between sildenafil and placebo. NS = not significant.
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Figure 4  –  Blood pressure (BP) behavior during the study. Diastolic BP in the supine position. P values refer to the comparisons
between sildenafil and placebo. NS = not significant.
Figure 5 – Blood pressure (BP) behavior during the study. Systolic BP in sitting position. P values refer to the comparisons between
sildenafil and placebo. NS = not significant.
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Figure 6   –  Blood pressure (BP) behavior during the study. Diastolic BP in sitting position. P values refer to the comparisons be-
tween sildenafil and placebo. NS = not significant.
There is abundant evidence pointing to the
relationship between ED and atherosclerosis and its
risk factors. Abnormalities in blood flow to the pe-
nis, which are frequent in patients with atherosclero-
sis and diabetes mellitus, are a common factor under-
lying organic ED. Approximately 40% of patients with
ED who are older than 50 years have associated ath-
erosclerosis. It is also estimated that ED occurs in
approximately 50% of patients with diabetes, regard-
less of the type; in these patients, the incidence of
ED seems to correlate with age and the severity of
diabetes (17,18). Patients with conventional risk fac-
tors for atherosclerotic coronary artery disease, such
as smoking, low levels of high-density lipoprotein
cholesterol and diabetes, are at increased risk for de-
veloping ED (19).
Most adverse events reported in the clinical
studies of sildenafil have been dose-dependent and
secondary to vasodilation; among such events, head-
ache, flushing and nasal congestion are the most fre-
quent. The effects of sildenafil on BP have been well
characterized (20-23). In physiological conditions,
sildenafil may lead to a mild to moderate decrease in
BP. In normotensive men, doses of 100 mg of
sildenafil may decrease systolic BP by up to 8-10 mm
Hg, and diastolic BP by up to 3-6 mm Hg (21). The
hypotensive effect of sildenafil may also be seen
among patients with hypertension, although its mag-
nitude may not be clinically significant in compari-
son to pretreatment BP levels (22,23). The peak hy-
potensive effect of sildenafil typically occurs approxi-
mately one hour after ingestion, and coincides with
peak plasma levels. In healthy men, the BP decreases
induced by sildenafil return to pretreatment levels
within 4 to 8 hours; these decreases are usually as-
ymptomatic (20).
Some authors have attempted to investigate
the safety of the concurrent administration of
sildenafil and anti-hypertensive drugs. Most of the
studies reported to date have looked at one anti-hy-
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pertensive agent used in isolation. Studies with di-
uretics, alpha-blockers, beta-blockers, ACE inhibitors,
angiotensin II receptor antagonists, and calcium-chan-
nel blockers have shown that these agents may usu-
ally be given concurrently with sildenafil with no
clinically significant hypotensive effect (22). Mild (2
to 4 mm Hg) decreases in systolic and diastolic BP
have been seen among patients with hypertension who
were on treatment with single anti-hypertensive drugs
and who took sildenafil (24). In addition, the type
and frequency of adverse events seen in such patients
have not differed from those that are seen among pa-
tients who are not in treatment for hypertension
(24,25). Sildenafil does not seem to have pharmaco-
dynamic interactions with anti-hypertensive drugs that
act through NO-independent mechanisms (23,25,26).
There is relatively little information in the
literature regarding the use of sildenafil in patients
with hypertension who are being treated with combi-
nations of anti-hypertensive drugs (11). Kloner et al.
have found no difference in the frequency of adverse
events in patients taking sildenafil who were on treat-
ment with one, two or three anti-hypertensive drugs.
In that study, the concurrent use of sildenafil and
multiple anti-hypertensive agents led to no apparent
increase in the frequency or severity of angina, myo-
cardial infarction or other serious cardiac events (27).
In the present study, the use of sildenafil sig-
nificantly improved the erectile function of Brazilian
men with hypertension who were under treatment with
multiple anti-hypertensive drugs. As compared with
patients who took a placebo, patients treated with
sildenafil had significant improvements in their abil-
ity to achieve and maintain an erection. Secondary
assessments confirmed the superiority of sildenafil
that led to global improvements in 87% of the pa-
tients. This proportion of improvement is similar to
that seen in other studies of sildenafil, including those
in patients without hypertension. The present study
also confirms that sildenafil produces no significant
effect on sexual desire. Importantly, our study dem-
onstrates the safety and tolerability of sildenafil in
patients with hypertension who are under treatment
with combinations of anti-hypertensive drugs. Treat-
ment with sildenafil was well tolerated, and dose ad-
justments during the study possibly contributed to a
reduction in the frequency of adverse events. As in
other studies, headache, vasodilation and dyspepsia,
typically of mild intensity, were the most frequent
treatment-related adverse events. Interestingly, the
effects of sildenafil on BP were not different from
those produced by placebo.
CONCLUSION
In conclusion, our results indicate that
sildenafil is efficacious, safe and well tolerated in the
treatment of ED in patients with hypertension who
are being treated with combinations of anti-hyperten-
sive drugs.
Drs. Ari Timerman, João C. F. Braga and
Marcus Malachias collaborated on the study.
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EDITORIAL COMMENT
Many researchers have suggested that erec-
tile dysfunction (ED) co-exists with other diseases
because they share common risk factors. Based on
published studies, ED has been found in patients with
hypertension, hyperlipidemia, diabetes mellitus, de-
pression, ischemic heart disease, coronary heart dis-
ease, peripheral vascular disease etc. However, pub-
lished information on the prevalence of these con-
current diseases in men with ED has been limited in
terms of the number or sample size of the studies.
ED is common among men taking anti-hy-
pertensive drugs to control blood pressure. Actually,
ED could be caused either by hypertension itself, by
the anti-hypertensive drugs or by the combination of
both.
The impact of ED on the patient’s quality of
life is much more important than the impact of hy-
pertension itself. Because of this, any well conducted
study to evaluate the efficacy and safety of the 5 PDE
inhibitors is very welcome.
Although this is a sponsored study, it was well
designed and it is important for to emphasize that even
patients receiving multiple anti-hypertensive drugs
can be treated with 5 PDE inhibitors. The results found
in the present study are quite promising. Otherwise,
perhaps a more reasonable success rate in such pa-
tients (presenting cardiovascular diseases) would be
around 70% (1).
Furthermore, despite the knowledge that these
drugs are safe even in critical patients and in doses as
high as 400 mg 4 times a day (2), the expected side
effects in this population seems to reach 40% (1).
In any event, the message of the study is that
5 PDE inhibitors are safe and present a high success
rate even in critical patients with hypertension who
are being treated with multiple anti-hypertensive
drugs.
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EDITORIAL COMMENT
This well-designed study and clearly written
paper is another important Brazilian contribution to
the international urological literature. Previously,
there was scant information on the effects of sildenafil
in hypertensive patients who are taking multiple an-
tihypertensive agents. This report demonstrates that
sildenafil is efficacious and safe for the treatment of
erectile dysfunction (ED) in men taking various com-
binations of antihypertensive drugs. The report also
demonstrates that despite its vasodilatory action,
sildenafil does not complicate treatment or interfere
with control of hypertension in these men.
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This is important information because it might
have been predicted that men with hypertension se-
vere enough to require multiple antihypertensive agents
would have more advanced ED, which is more diffi-
cult to treat successfully. In fact, analyzing the data
presented in the tables, the pre-treatment scores on the
erectile function domain (questions 1-5 and 15) of the
International Index of Erectile Function (IIEF) were
12.26 and 12.93 in the placebo and sildenafil groups.
These pre-treatment scores are slightly lower than the
pre-treatment scores seen in most other sildenafil clini-
cal trials, suggesting that the men in this study might
have had slightly more severe ED than men in other
studies. The post-treatment score on the erectile func-
tion domain in the placebo group in this study rose
only to 14.75, demonstrating a mild placebo effect,
while the post-treatment score in the sildenafil group
rose to 24.14, clearly demonstrating the efficacy of
sildenafil. The score of 24.14 is somewhat higher than
has been reported in most other sildenafil clinical tri-
als, showing that sildenafil is as effective in men using
multiple antihypertensive agent combinations as in
many other groups of men with ED.
The authors are to be congratulated for com-
pleting an excellent study that fills one of the gaps in
the international literature on sexual medicine.
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